Press Release: Prevision Medicine adds Multiple Myeloma to their personalized drug-testing portfolio

Prevision Medicine, a Zurich-based techbio start-up and ETH spin-off, announced the expansion of its proprietary personalized drug screening platform, PrevisionOne™, to include Multiple Myeloma (MM). 

Currently designed for research-use-only (RUO), the test supports oncologists to rapidly identify the most effective treatment combinations for each individual MM patient. The test generates patient-specific drug sensitivity profiles, aiding faster, data-driven therapeutic decisions in the treatment of MM patients. Following the successful launch of its drug screening solutions for Acute Myeloid Leukemia and Glioblastoma, Prevision Medicine continues to expand its platform into additional high-need indications. 

MM is an incurable cancer of the bone marrow. Effective management requires timely and carefully sequenced treatment decisions to control symptoms, prevent organ damage, and extend survival. Today, there are numerous approved treatment options for MM across multiple drug classes. These therapies are often combined in doublet, triplet, or quadruplet regimens for both newly diagnosed and relapsed or refractory patients. While this expanding therapeutic landscape has improved outcomes, it has also increased the complexity of treatment selection. Identifying the most effective combination for an individual patient at a given time is a critical and challenging task. 

Prevision Medicine’s MM Drug Screening Test addresses this challenge by systematically evaluating available treatment options on primary cancer and healthy cells to determine the most effective combination for each patient. Using only a small sample of bone marrow, the test provides actionable insights that support personalized, evidence-based treatment decisions within an increasingly complex therapeutic space.

The MM RUO test is built on findings from a comprehensive observational clinical study recently published in Nature Cancer conducted in collaboration with the University Hospital Zurich. The study demonstrates that image-based ex vivo drug testing (“pharmacoscopy”) can accurately predict clinical patient responses to both standard-of-care and complex immunotherapy-containing treatment regimens.

“Despite significant therapeutic advances, treating Multiple Myeloma remains highly complex, requiring careful selection of combination therapies for each individual patient,” said Philip Zimmermann, CEO of Prevision Medicine. “PrevisionOne’s high-throughput drug screening capabilities enable oncologists to navigate this complexity with  functional and data-driven therapeutic decisions of MM patients,- helping identify the most effective treatment combinations to improve disease control and patient outcomes.”

Download the full press release here.